Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean...

Descripción completa

Detalles Bibliográficos
Autores principales: Akmansu, Muge, Buyukberber, Suleyman, Iren, Sevilay, Demirci, Umut, Kanyilmaz, Gul, Coskun, Ugur, Bora, Huseyin
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: December 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100271/
https://www.ncbi.nlm.nih.gov/pubmed/21611102
http://dx.doi.org/10.1159/000323204
_version_ 1782204174042136576
author Akmansu, Muge
Buyukberber, Suleyman
Iren, Sevilay
Demirci, Umut
Kanyilmaz, Gul
Coskun, Ugur
Bora, Huseyin
author_facet Akmansu, Muge
Buyukberber, Suleyman
Iren, Sevilay
Demirci, Umut
Kanyilmaz, Gul
Coskun, Ugur
Bora, Huseyin
author_sort Akmansu, Muge
collection PubMed
description We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%.
format Text
id pubmed-3100271
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-31002712011-05-24 Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer Akmansu, Muge Buyukberber, Suleyman Iren, Sevilay Demirci, Umut Kanyilmaz, Gul Coskun, Ugur Bora, Huseyin Case Rep Oncol Published: December 2010 We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%. S. Karger AG 2010-12-17 /pmc/articles/PMC3100271/ /pubmed/21611102 http://dx.doi.org/10.1159/000323204 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: December 2010
Akmansu, Muge
Buyukberber, Suleyman
Iren, Sevilay
Demirci, Umut
Kanyilmaz, Gul
Coskun, Ugur
Bora, Huseyin
Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title_full Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title_fullStr Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title_full_unstemmed Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title_short Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
title_sort cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer
topic Published: December 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100271/
https://www.ncbi.nlm.nih.gov/pubmed/21611102
http://dx.doi.org/10.1159/000323204
work_keys_str_mv AT akmansumuge cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT buyukberbersuleyman cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT irensevilay cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT demirciumut cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT kanyilmazgul cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT coskunugur cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer
AT borahuseyin cetuximabconcomitantwithsecondlineradiationtherapyinpatientswithlocallyadvancedrecurrentsquamouscellheadandneckcancer

Ejemplares similares